Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Posted: August 14, 2022 at 2:33 am

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.

Original post:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Related Posts